Dynavax Technologies Corporation products
C
-
CpG 1018® (vaccine adjuvant)
-
Utilized in their marketed vaccine HEPLISAV-B® and incorporated into several COVID-19 vaccines globally.
-
H
-
HEPLISAV-B® — Hepatitis B vaccine (recombinant), adjuvanted
-
Indication: Prevention of hepatitis B infection in adults. Administered in just two doses in one month for series completion.
-
P
-
Plague Vaccine Program
-
Investigational candidate: rF1V vaccine for plague prevention, adjuvanted with CpG 1018 under development through a collaboration with the U.S. Department of Defense.
-
S
-
Shingles Vaccine Program (Z-1018)
-
Investigational herpes zoster (shingles) vaccine, adjuvanted with CpG 1018; currently in Phase 1/2 trials, showing strong immune response and improved safety compared to existing vaccines.
No comments:
Post a Comment